← Back
Data updated: Mar 29, 2026
TORRENT
CardiovascularNeurologyDermatology
Generics
TORRENT is a generic drug manufacturer focused on Cardiovascular, Neurology, Dermatology.
2000
Since
83
Drugs
-
Trials
1070
Approved (2yr)
Key Drugs
EZETIMIBE AND SIMVASTATIN
ezetimibe
NPC1L1 6 indications · 2017
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE
chlordiazepoxide hydrochloride
4 indications · 2020
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
amlodipine besylate
AT1 receptor 3 indications · 2016
AMLODIPINE BESYLATE AND VALSARTAN
amlodipine besylate
Calcium channel 3 indications · 2013
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
amlodipine besylate
Calcium channel 3 indications · 2012
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
BUPROPION HYDROCHLORIDE 2026-02-25
Labeling
LURASIDONE HYDROCHLORIDE 2026-02-24
Labeling
LURASIDONE HYDROCHLORIDE 2026-02-24
Labeling
PREGABALIN 2026-02-24
PREGABALIN 2026-02-23
Labeling
PREGABALIN 2026-02-23
Labeling
PREGABALIN 2026-02-23
Labeling
DOXYCYCLINE HYCLATE 2026-02-19
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 47%
13 drugs Phase 3: 1
Neurology 20%
6 drugs
Dermatology 13%
3 drugs Phase 3: 1
Respiratory 10%
3 drugs
Oncology 10%
3 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
OTSUKA big-pharma
Neurology, Dermatology, Cardiovascular, Oncology, Respiratory
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Oncology, Respiratory
Baxter specialty
Cardiovascular, Oncology, Dermatology
LEDERLE big-pharma
Cardiovascular, Neurology, Dermatology, Respiratory
Active (51)
SACUBITRIL AND VALSARTAN VENXXIVA FIDAXOMICIN NILOTINIB HYDROCHLORIDE PAZOPANIB HYDROCHLORIDE ORMALVI PENCICLOVIR ESLICARBAZEPINE ACETATE LENALIDOMIDE MACITENTAN SORAFENIB TOSYLATE CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE NITISINONE TERIFLUNOMIDE ROFLUMILAST TADALAFIL EZETIMIBE AND SIMVASTATIN SILODOSIN OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE OLMESARTAN MEDOXOMIL ROSUVASTATIN CALCIUM DEFERASIROX ARIPIPRAZOLE DARIFENACIN HYDROBROMIDE ESOMEPRAZOLE MAGNESIUM CELECOXIB SOLIFENACIN SUCCINATE MOXIFLOXACIN HYDROCHLORIDE SIROLIMUS TELMISARTAN RABEPRAZOLE SODIUM RANOLAZINE RASAGILINE MESYLATE AMLODIPINE BESYLATE AND VALSARTAN AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE APREPITANT VENLAFAXINE HYDROCHLORIDE LAMOTRIGINE ANAGRELIDE HYDROCHLORIDE FLUVOXAMINE MALEATE DICLOFENAC POTASSIUM RANITIDINE HYDROCHLORIDE ACYCLOVIR POTASSIUM CITRATE CARBAMAZEPINE DAPSONE NYSTATIN ACETAZOLAMIDE DOXYCYCLINE HYCLATE ERYTHROMYCIN
Discontinued (27)
BUPROPION HYDROCHLORIDE PREGABALIN TELMISARTAN AND HYDROCHLOROTHIAZIDE OLANZAPINE TRAZODONE HYDROCHLORIDE PRUCALOPRIDE SUCCINATE FLUOXETINE HYDROCHLORIDE MOMETASONE FUROATE CLOBETASOL PROPIONATE FLUPHENAZINE HYDROCHLORIDE METFORMIN HYDROCHLORIDE SEVELAMER CARBONATE MINOCYCLINE HYDROCHLORIDE MONTELUKAST SODIUM FEBUXOSTAT MEMANTINE HYDROCHLORIDE TOLTERODINE TARTRATE ITRACONAZOLE IBUPROFEN AND FAMOTIDINE APREMILAST VALSARTAN FENOFIBRATE (MICRONIZED) AMLODIPINE AND OLMESARTAN MEDOXOMIL DULOXETINE HYDROCHLORIDE DIMETHYL FUMARATE NYSTATIN AND TRIAMCINOLONE ACETONIDE TELMISARTAN AND AMLODIPINE
Company Info
- First Approval
- 2000-11-30
- Latest
- 2026-01-27
- Applications
- 91